FAK和Wnt在卵巢癌铂耐药中的研究进展

Advances in the study of FAK and Wnt in platinum resistance in ovarian cancer

卵巢癌是人类生殖器官最常见的恶性肿瘤之一,在所有妇科恶性肿瘤中病死率第一位。大多数的患者诊断时已为卵巢癌晚期,且对铂类化疗耐药。黏着斑激酶(FAK)是一种非受体酪氨酸激酶,通常从细胞黏附转导信号来调节多种生物细胞功能,包括细胞存活、癌细胞的迁移和侵袭。FAK、Wnt/β-catenin通路参与卵巢癌铂化疗耐药的机制,因此FAK、Wnt被认为是高价值的药物治疗靶点,特别是联合其他药物,有效逆转铂化疗耐药。

Ovarian cancer is one of the most common malignant tumors in human reproductive organs,and the fatality rate is the first among all gynecological malignant tumors.Most patients are diagnosed with advanced ovarian cancer that is resistant to platinum-based chemotherapy.Adhesion spot kinase(FAK)is a non-receptor tyrosine kinase that normally transduces signals from cell adhesion to regulate a variety of biological cell functions,including cell survival,cancer cell migration,and invasion.Mechanism of FAK,Wnt/β-catenin pathway involved in platinum chemotherapy resistance of ovarian cancer.FAK and Wnt are considered as high-value drug therapeutic targets,especially in combination with other drugs to effectively reverse platinum chemotherapy resistance.